-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, WGGjNgYCPWjGVfLi5u1xA4w3vnzGsV8YXeE0QDSKC5gsNbl2+iBMScPqjz36zfIE IrN+pfaQ26Xf3r7OuGOYIw== 0000929638-01-500084.txt : 20010424 0000929638-01-500084.hdr.sgml : 20010424 ACCESSION NUMBER: 0000929638-01-500084 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20010423 GROUP MEMBERS: AIM HIGH ENTERPRISES, INC. GROUP MEMBERS: KAIROS PARTNERS GP, LLC GROUP MEMBERS: KAIROS PARTNERS LP GROUP MEMBERS: KAIROS PARTNERS, LP GROUP MEMBERS: STONEGATE PARTNERS, LLC SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: IMMUCOR INC CENTRAL INDEX KEY: 0000736822 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 222408354 STATE OF INCORPORATION: GA FISCAL YEAR END: 0531 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: SEC FILE NUMBER: 005-37473 FILM NUMBER: 1608199 BUSINESS ADDRESS: STREET 1: 3130 GATWAY STREET 2: PO BOX 5625 CITY: NORCROSS STATE: GA ZIP: 30091 BUSINESS PHONE: 7704412051 MAIL ADDRESS: STREET 1: 3130 GATEWAY DR STREET 2: P O BOX 5625 CITY: NORCROSS STATE: GA ZIP: 30091-5625 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: KAIROS PARTNERS LP CENTRAL INDEX KEY: 0001122689 STANDARD INDUSTRIAL CLASSIFICATION: [] FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: 600 LONGWATER DRIVE STREET 2: SUITE 204 CITY: NORWELL STATE: MA ZIP: 02061 BUSINESS PHONE: 7816351100X1123 MAIL ADDRESS: STREET 1: 600 LONGWATER DR. STREET 2: SUITE 204 CITY: NORWELL STATE: MA ZIP: 02061 SC 13D/A 1 a983498.txt AMENDMENT TO SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (RULE 13D-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13D-1(A) AND AMENDMENTS THERETO FILED PURSUANT TO 13D-2(A) (AMENDMENT NO. 2)* Immucor, Inc. (Name of Issuer) Common Stock, $.10 par value (Title of Class of Securities) 452526106 (CUSIP Number) James F. Rice, Managing Director c/o Aim High Enterprises, Inc. 600 Longwater Drive, Suite 204 Norwell, MA 02061 (781) 635-1121 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) April 19, 2001 (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(b)(3) or (4), check the following box (). NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7(b) for other parties to whom copies are to be sent. (Continued on the following pages) (Page 1 of 9 Pages) - ---------------- * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 452526106 13D/A PAGE 1 OF 1 - -------------------------------------------------------------------------------- 1 NAMES OF REPORTING PERSONS S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) Kairos Partners, LP (Tax ID: 04-3521249) Kairos Partners GP, LLC Aim High Enterprises, Inc. StoneGate Partners, LLC - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (A) [ ] (B) x - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS (SEE INSTRUCTIONS) WC--SEE ITEM 3 - -------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E) [ ] - -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION Kairos Partners, LP is a Delaware limited partnership. Kairos Partners GP, LLC is a Delaware limited liability corporation. Aim High Enterprises, Inc. is a Delaware corporation. StoneGate Partners, LLC is a Massachusetts limited liability corporation. - -------------------------------------------------------------------------------- 7 SOLE VOTING POWER None NUMBER OF --------------------------------------------------------- SHARES 8 SHARED VOTING POWER BENEFICIALLY OWNED BY 584,300 shares--See Item 5 EACH --------------------------------------------------------- REPORTING 9 SOLE DISPOSITIVE POWER PERSON WITH None --------------------------------------------------------- 10 SHARED DISPOSITIVE POWER 584,300 shares--See Item 5 - -------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 584,300 shares--See Item 5 - -------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [ ] Not Applicable. - -------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 8.0% (based on 7,277,617 shares of Common Stock outstanding as of January 16, 2001, as reported by the Issuer in its Form 10-Q for the quarter ended November 30, 2000). - -------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) Kairos Partners, LP--PN Kairos Partners GP, LLC--OO (limited liability corporation) Aim High Enterprises, Inc.--CO StoneGate Partners, LLC--OO (limited liability corporation) - -------------------------------------------------------------------------------- ITEM 1. SECURITY AND ISSUER: (a) This Amendment No. 2 relates to the common stock, $.10 par value per share, of Immucor, Inc. (the "Common Stock"). (b) The names and addresses of the principal executive officers of the Issuer are as follows: Edward L. Gallup, President and Chief Executive Officer Ralph A. Eatz, Senior Vice President - Operations Dr. Gioacchhino De Chirico, Director of European Operations and President, Immucor Italia S.r.1 Steven C. Ramsey, Vice President - Chief Financial Officer and Secretary Patrick Waddy, President of Dominion Biologicals Limited and European Finance Director Address: c/o Immucor, Inc. 3130 Gateway Drive P.O. Box 5625 Norcross, Georgia 30091 ITEM 2. IDENTITY AND BACKGROUND 1. (a) Kairos Partners, LP, ("Kairos") a limited partnership organized under the laws of the State of Delaware. (b) Address: c/o Aim High Enterprises, Inc. 600 Longwater Drive, Suite 204 Norwell, MA 02061 (c) Principal Business: Investments (d) During the last five years, Kairos has not been convicted in a criminal proceeding. (e) During the last five years, Kairos was not a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. 2. (a) Kairos Partners GP, LLC, a limited liability corporation organized under the laws of the State of Delaware ("Kairos GP"). Kairos GP is the general partner of Kairos. (b) Address: c/o Aim High Enterprises, Inc. 600 Longwater Drive, Suite 204 Norwell, MA 02061 (c) Principal Business: Investments (d) During the last five years, Kairos GP has not been convicted in a criminal proceeding. (e) During the last five years, Kairos GP was not a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. 3. (a) Aim High Enterprises, Inc. jointly controls Kairos GP with StoneGate Partners, LLC (see below). (b) Address: c/o Aim High Enterprises, Inc. 600 Longwater Drive, Suite 204 Norwell, MA 02061 (c) Principal Business: Investments (d) During the last five years, Aim High Enterprises, Inc. has not been convicted in a criminal proceeding. (e) During the last five years, Aim High Enterprises, Inc. was not a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. (f) Aim High Enterprises, Inc. is a corporation organized under the laws of the State of Delaware. 4. (a) StoneGate Partners, LLC jointly controls Kairos GP with Aim High Enterprises, Inc. (see above). (b) Address: StoneGate Partners, LLC 45 Milk Street, 7th Floor Boston, MA 02109 (c) Principal Business: Investments (d) During the last five years, StoneGate Partners, LLC has not been convicted in a criminal proceeding. (e) During the last five years, StoneGate Partners, LLC was not a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. (f) StoneGate Partners, LLC is limited liability corporation organized under the laws of the Commonwealth of Massachusetts. ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION: The amount of funds used in acquiring the Common Stock was $2,353,320.46. The source of these funds was Kairos' current cash equivalent assets (working capital). ITEM 4. PURPOSE OF TRANSACTION: At the time that Kairos acquired the shares of Common Stock which are reported hereby, such shares were acquired for investment purposes. Kairos reserves the right from time to time to acquire additional shares, or to dispose of some or all of its shares. (a) Not applicable (b) Not applicable (c) Not applicable. (d) By letter from Kairos to the Issuer, dated April 9, 2001, a copy of which is attached to this Amendment #2 as Exhibit 99.1, John F. White, Principal of Kairos, requested that the Issuer add a designee of Kairos to the Issuer's Board of Directors. In the event that the Issuer does not respond to Kairos' letter, Kairos may consider other options available to it with respect to possible designees to the Issuer's Board of Directors. (e) Not applicable. (f) See Item (d) above. (g) Not applicable. (h) Not applicable. (i) Not applicable. (j) Not applicable. ITEM 5. INTEREST IN SECURITIES OF THE ISSUER: a) The following table sets forth the aggregate number and percentage (based on 7,277,617 shares of Common Stock outstanding as of January 16, 2001 as reported by the Issuer in its Form 10-Q for the quarter ended November 30, 2000) of outstanding shares of Common Stock owned beneficially by each reporting person named in Item 2, as of April 19, 2001: - -------------------------------------------------------------------------------- Name Shares of Common Stock Percentage of Beneficial Beneficially Owned Ownership - -------------------------------------------------------------------------------- - -------------------------------------------------------------------------------- Kairos Partners, LP 584,300 8.0% - -------------------------------------------------------------------------------- Kairos Partners GP, LLC(1) 584,300 8.0% - -------------------------------------------------------------------------------- Aim High Partners, Inc.(1) 584,300 8.0% - -------------------------------------------------------------------------------- StoneGate Partners, LLC(1) 584,300 8.0% - -------------------------------------------------------------------------------- - ----------------------- (1) The reporting person disclaims beneficial ownership of these securities except to the extent of his/its equity interest therein. (b) Kairos has sole power to vote and to dispose of 584,300 shares of Common Stock, representing 8.0% of the outstanding Common Stock. Kairos GP, by virtue of being the general partner of Kairos, may be deemed to have shared power to vote and to dispose of 584,300 shares of Common Stock, representing 8.0% of the outstanding Common Stock. Aim High Enterprises, Inc., by virtue of being a joint controller of Kairos GP with StoneGate Partners, LLC, may be deemed to have shared power to vote and to dispose of 584,300 shares of Common Stock, representing 8.0% of the outstanding Common Stock. StoneGate Partners, LLC, by virtue of being a joint controller of Kairos GP with Aim High Enterprises, Inc., may be deemed to have shared power to vote and to dispose of 584,300 shares of Common Stock, representing 8.0% of the outstanding Common Stock. (c) The following is a description of all transaction in shares of Common Stock of the Issuer by the reporting person identified in Item 2 of this Schedule 13D effected from November 20, 2000 to April 19, 2001: See Appendix A. (d) Not applicable (e) Not applicable ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER : Not applicable. ITEM 7. MATERIAL TO BE FILED AS EXHIBITS. Exhibit 99.1--Letter to Board of Directors of the Issuer regarding Kairos' proposed designee to the Board of Directors of Issuer. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. -------------------------------- (Date) -------------------------------- (Signature) -------------------------------- James F. Rice Managing Director Aim High Enterprises, Inc.
Appendix A - ----------------------------------------------------------------------------------------- Name of Date of Purchase Number of Purchase or Sale Shareholder or Sale Shares Purchased Price Per Share or (Sold) - ----------------------------------------------------------------------------------------- Kairos 11/20/00 400 $4.4103 - ----------------------------------------------------------------------------------------- Kairos 11/21/00 (900) $(4.6875) - ----------------------------------------------------------------------------------------- Kairos 11/21/00 (500) $(5.25) - ----------------------------------------------------------------------------------------- Kairos 11/21/00 (500) $(4.625) - ----------------------------------------------------------------------------------------- Kairos 11/21/00 (100) $(4.6875) - ----------------------------------------------------------------------------------------- Kairos 11/21/00 (400) $(5.25) - ----------------------------------------------------------------------------------------- Kairos 11/21/00 (300) $(4.875) - ----------------------------------------------------------------------------------------- Kairos 11/21/00 (300) $(4.8125) - ----------------------------------------------------------------------------------------- Kairos 11/21/00 (300) $(4.625) - ----------------------------------------------------------------------------------------- Kairos 11/21/00 (200) $(5.125) - ----------------------------------------------------------------------------------------- Kairos 11/21/00 (200) $(4.8125) - ----------------------------------------------------------------------------------------- Kairos 11/21/00 (200) $(4.6875) - ----------------------------------------------------------------------------------------- Kairos 11/21/00 (100) $(5.3125) - ----------------------------------------------------------------------------------------- Kairos 11/21/00 (100) $(5.1875) - ----------------------------------------------------------------------------------------- Kairos 11/21/00 (100) $(5.0625) - ----------------------------------------------------------------------------------------- Kairos 11/21/00 (100) $(5.00) - ----------------------------------------------------------------------------------------- Kairos 11/21/00 (450) $(4.875) - ----------------------------------------------------------------------------------------- Kairos 11/21/00 (100) $(4.9375) - ----------------------------------------------------------------------------------------- Kairos 11/22/00 5,000 $4.2708 - ----------------------------------------------------------------------------------------- Kairos 11/24/00 500 $4.4030 - ----------------------------------------------------------------------------------------- Kairos 11/24/00 (500) $4.0175 - ----------------------------------------------------------------------------------------- Karios 11/29/00 6,000 $4.6349 - ----------------------------------------------------------------------------------------- Karios 11/29/00 1,000 $4.5139 - ----------------------------------------------------------------------------------------- Karios 11/29/00 1,000 $4.6389 - ----------------------------------------------------------------------------------------- Karios 11/29/00 500 $4.5278 - ----------------------------------------------------------------------------------------- Kairos 11/29/00 100 $4.5152 - ----------------------------------------------------------------------------------------- Kairos 12/1/00 2,500 $4.6136 - ----------------------------------------------------------------------------------------- Kairos 12/4/00 5,000 $4.4474 - ----------------------------------------------------------------------------------------- Kairos 12/4/00 5,000 $4.26 - ----------------------------------------------------------------------------------------- Kairos 12/4/00 3,000 $4.3846 - ----------------------------------------------------------------------------------------- Kairos 12/4/00 3,000 $4.26 - ----------------------------------------------------------------------------------------- Kairos 12/4/00 2,500 $4.26 - ----------------------------------------------------------------------------------------- Kairos 12/4/00 2,000 $4.323 - ----------------------------------------------------------------------------------------- Kairos 12/4/00 1,800 $4.3846 - ----------------------------------------------------------------------------------------- Kairos 12/5/00 1,900 $4.00 - ----------------------------------------------------------------------------------------- Kairos 12/6/00 2,500 $4.0723 - ----------------------------------------------------------------------------------------- Kairos 12/18/00 1,000 $3.8265 - ----------------------------------------------------------------------------------------- Kairos 4/17/01 900 $2.5256 - ----------------------------------------------------------------------------------------- - ----------------------------------------------------------------------------------------- Kairos 4/18/01 3,500 $2.4103 - ----------------------------------------------------------------------------------------- Kairos 4/18/01 3,500 $2.3902 - ----------------------------------------------------------------------------------------- Kairos 4/18/01 2,500 $2.3902 - ----------------------------------------------------------------------------------------- Kairos 4/18/01 2,000 $2.4103 - ----------------------------------------------------------------------------------------- Karios 4/18/01 2,000 $2.4103 - ----------------------------------------------------------------------------------------- Karios 4/18/01 2,000 $2.4103 - ----------------------------------------------------------------------------------------- Karios 4/18/01 2,000 $2.4103 - ----------------------------------------------------------------------------------------- Karios 4/18/01 2,000 $2.4103 - ----------------------------------------------------------------------------------------- Karios 4/18/01 2,000 $2.3902 - ----------------------------------------------------------------------------------------- Karios 4/18/01 2,000 $2.3902 - ----------------------------------------------------------------------------------------- Karios 4/18/01 1,500 $2.46 - ----------------------------------------------------------------------------------------- Karios 4/18/01 1,500 $2.36 - ----------------------------------------------------------------------------------------- Karios 4/18/01 800 $2.3571 - ----------------------------------------------------------------------------------------- Karios 4/18/01 600 $2.4737 - -----------------------------------------------------------------------------------------
The shares of Common Stock were purchased by Kairos in the over-the-counter market. EX-99.1 2 a984541.txt LETTER KAIROS PARTNERS April 9, 2001 Mr. Daniel T. McKeithan Director Immucor Inc. 3130 Gateway Drive Norcross, GA 3091-5625 Dear Mr. McKeithan: As you know, the Kairos Partners Fund is a significant shareholder of Immucor stock, owning approximately 8%. We are very positive about the long-term potential for Immucor. However, we have concerns about the current strategic plans of the Company. We have two actions we would like you to undertake: First, we want you to ADD ONE OF OUR ASSOCIATES, JACK MCGUIRE, TO YOUR BOARD OF DIRECTORS. Mr. McGuire would bring market, customer and product knowledge and over 20 years of experience in the health care industry to your Board. Enclosed is a copy of Mr. McGuire's CV for your reference. We believe Immucor's shareholders will perceive Mr. McGuire's addition to the Board as a positive indicator of the Board's plans for change in the performance and value of the Company. Mr. McGuire is prepared to assist the management team in developing and implementing short-term strategies that will increase sales and gross margins. Some of you already know Jack and me. We believe our existing relationships will increase the potential for Mr. McGuire aiding Immucor. Secondly, we want MANAGEMENT TO PROVIDE IMMUCOR SHAREHOLDERS WITH THEIR PLANS TO REDUCE THE CURRENT DEBT LEVELS. We perceive Immucor's debt level as a major issue. Immucor's Debt Service is not only using all the Company's free cash, thereby restricting and limiting cash needs for funding of the business, but also it is our understanding that Immucor must repay approximately $20 million of this debt in the next 12-18 months. On a related subject, we are also concerned with management's practice of borrowing funds to buy back stock. We hope you will support the opportunity of Mr. McGuire's service on your Board. We look forward to reviewing your debt reduction plans in the near future. Sincerely, /s/ John F. White John F. White Principal Kairos Partners, LP JFW/sh Enc. cc: E. Gallup/D. Lanson/D. Smith/R. Eatz/B. Papesh/J. Rosen/G. DeChirico 600 Longwater Drive (degree) Suite 204 (degree) Norwell, MA 02061 Telephone 781-635-1000 (degree) Fax 781-635-1110 JOHN F. (JACK) MCGUIRE P.O. Box 113 Still River, MA 01467 978-456-7357 (home) 508-490-9565 (office) - ------------------------------------------------------------------------------- General Management Executive with 19 years demonstrated success, both domestic and international, in general management, sales and marketing, and strategy developing. Strong record of above average profit and sales growth, market valued new product introductions, organizational development and performance improvement initiatives with hands-on approach to key customers. Consistently relied upon to re-energize organization. Key areas of expertise include: o Strategic Planing o Turn Around Management o Market Based Product o Market Analysis and Planning Introductions and Programs o Organization Energizing and o Organizational Mergers Alignment o Continuous Process Improvement o Investment Community Relationships and Capital Raising HEMASURE INC., MARLBOROUGH, MA - ------------------------------------------------------------------------------- PRESIDENT, CEO AND DIRECTOR (1997-PRESENT) Total company responsibility for this publicly traded Company of - 50 employees in a turn around situation. Challenges include redirection of business while maintaining key personnel, reestablishing employee morale while changing the corporate culture, extricating the Company from prior destructive commitments and legal actions, repositioning the Company with the investment community, and retrenching the Company back to the development stage in order to establish a competitive profitable product offering. Selective accomplishments include: o Removed/shut down non-strategic operations in 9 months o Redirected Company strategy resulting in new product initiative within 13 months o Reestablished Company culture, retaining all critical personnel throughout the time period o Reestablished credibility with investment community, and raised in excess of $7MM to continue operations while awaiting new product ORTHO DIAGNOSTIC SYSTEMS, INC. (SUBSIDIARY OF JOHNSON & JOHNSON), RARITAN, NJ (1988-1997) - ------------------------------------------------------------------------------- VICE PRESIDENT AND GENERAL MANAGER, BLOOD BANK BUSINESS UNITY (1996-1997) P&L responsibility for $200MM per year medical diagnostics business with 150 employees. Challenges included merging of two former business units and reversing stagnant sales and declining profits. Selected accomplishments include: o Drove sales growth 2-3x market growth o Achieved unit cost reduction of 27% and 35% for two key product lines o Reversed 28-month back order resulting in a sales increase of $5MM o Restructured R&D approach resulting in a 12-month reduction in the New Product cycle Time o Reversed a negative FDA audit VICE PRESIDENT, NORTH AMERICAN SALES & MARKETING (1994-1995) Managed the sales, marketing and technical support functions for all product lines for North America and for International distributors - total sales of $225MM. Sales had been flat to declining for 2-3 years. Selected accomplishments include: o Grew sales 12% and 28% in 1995 and 1996 without any significant new products o Restructured sales organization along customer/market lines and reduced headcount by 10% MANAGING DIRECTOR, ODS UK (1990-1994) AND ODS BELGIUM (1992-1994) P&L responsibility for a $3MM UK based company and later added a $3MM Belgian based company. Total staff size (combined) of 60. o Grew UK sales to $17MM in 4 years and reversed negative net income o Grew Belgian sales twofold, reduced headcount by 40% and reversed negative net income o Reduced operating expenses from > 50% to 30% of sales MARKETING DIRECTOR, AIDS & HEPATITIS BUSINESS UNIT (1998-1990) Responsibility for all marketing and sales support programs worldwide with 15 direct reports. Developed marketing strategy, marketing plans, licensing negotiation strategy and introduction plans for HCV diagnostic tests. Selected accomplishments include: Developed and implemented strategy to successfully position Ortho to enter AIDS and Hepatitis screening market with the introduction of HCV tests and achieve market leadership within 5 years. E.I. DUPORT DE NEMOURS & CO., WILMINGTON, DE (1977-1988) - ------------------------------------------------------------------------------- NATIONAL SALES MANAGER, AIDS & HEPATITIS BUSINESS (1985-1988) Managed all sales and technical services in North America from inception of business. Grew sales from 0 to $10MM. NEW ENGLAND NUCLEAR CORPORATION (SUBSIDiARY OF DUPONT), BOSTON, MA (1977-1985) - ------------------------------------------------------------------------------- VARIOUS ASSIGNMENTS Various assignments in three different business units including sales management, marketing management, strategic planning management and product management. XEROX CORPORATION, BOSTON, MA (1974-1976) - ------------------------------------------------------------------------------- SALES Sales position in copier division. - ------------------------------------------------------------------------------- U.S. MARINE CORPS (1969-1972) Captain - ------------------------------------------------------------------------------- MBA, MARKETING, Harvard University, Cambridge, MA (1974) BS, CHEMISTRY, Iona College, New Rochelle, NY (1968) - ------------------------------------------------------------------------------- Board of Trustees, National Blood Foundation - ------------------------------------------------------------------------------- Married, two children. Interests include golf, fly fishing, skiing and carpentry. -----END PRIVACY-ENHANCED MESSAGE-----